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 In silico Study Directed Towards Identification the Key Structural 1 
Feature of GyrB Inhibitors Targeting MTB DNA Gyrase: HQSAR, 2 
CoMSIA and Molecular Dynamics Simulations 3 
MTB DNA gyrase subunit B (GyrB) has been identified as promising target for 4 
rational drug design against fluoroquinolone drug resistant tuberculosis. In this 5 
study, we attempted to identify the key structural feature for highly potent GyrB 6 
inhibitors through 2D-QSAR using HQSAR, 3D-QSAR using CoMISA and MD 7 
simulations approaches on a series of thiazole urea core derivatives. The best 8 
HQSAR and CoMSIA models based on IC50 and MIC displayed the structural basis 9 
required for good activity against both GyrB enzyme and mycobacterial cell. MD 10 
simulations and binding free energy analysis using MM-GBSA and waterswap 11 
calculations revealed that urea core of inhibitors has strongest interaction with 12 
Asp79 via hydrogen bond interactions. In addition, cation-pi interaction and 13 
hydrophobic interactions of R2 subsituent with Arg82 and Arg141 help to enhance 14 
the binding affinity in GyrB ATPase binding site. Thus, the present study 15 
beneficially provides crucial structural feature and a structural concept for rational 16 
design of novel DNA gyrase inhibitors with improved biological activities against 17 
both enzyme and mycobacterial cell; good pharmacokinetic properties and drug 18 
safely profiles. 19 
Keywords: GyrB inhibitors; Binding free energy; CoMSIA; HQSAR; MD 20 
simulations, DNA gyrase 21 
Introduction 22 
Tuberculosis, TB caused by Mycobacterium tuberculosis (MTB) is one of the top 23 
10 causes of death worldwide and the leading cause from a single infectious agent. There 24 
are 1.6 million deaths and 10.0 million people developed TB disease in 2017 [1].  Based 25 
on drug resistant tuberculosis, potential targets for tuberculosis drug development have 26 
been validated [2-4]. DNA gyrase had been identified as potential target for anti-27 
tuberculosis drug discovery and the attractive target of fluoroquinolones, second-line 28 
drug for multidrug resistant tuberculosis (MDR-TB) [5-9].  This enzyme involved in the 29 
DNA replication mechanism. DNA gyrase consisted two subunits, DNA gyrase subunit 30 
A (GyrA) and DNA gyrase subunit B (GyrB) domains, in the holoenzyme complex as a 31 
heterotetramer A2B2 [10-12]. Only GyrA interacted with DNA and did the DNA cleavage 32 
 
 
and relegation processes by tyrosine residue in the catalytic site [13,14], whereas the 1 
GyrB promoted the ATP hydrolysis to process the catalytic cycles [15]. Fluroquinolone 2 
drugs interacted with DNA in GyrA domain to create conformational changes of DNA 3 
gyrase enzyme [5]. However, resistance to fluoroquinolones may occur spontaneously 4 
due to the mutation of fluoroquinolone binding site leading to extensively drug resistant 5 
tuberculosis (XDR-TB) [16-19]. To overcome fluoroquinolone drug resistant, novel 6 
DNA gyrase inhibitors which shown the alternative inhibition mechanism at the ATPase 7 
binding site of GyrB were proposed [7-9] such as 4-aminoquinolines [20], thiazole–8 
aminopiperidines [21], pyrrolamides [22], 2-amino-5-phenylthiophene-3-carboxamides 9 
[23], quinoline–aminopiperidines [24], benzofurans [25] and benzo[d]isothiazoles [26]. 10 
Thiazole urea cores derivatives [27, 28] were discovered as GyrB inhibitors by a scaffold-11 
hopping approach. Some compounds showed good potency against GyrB enzyme and M. 12 
tuberculosis with high correlation between GyrB inhibitory activity and anti-microbial 13 
activity. Based on the promising results from this report, lead optimization process was 14 
required. However, these compounds show low pharmacokinetic properties. The 15 
optimization of thiazole urea derivatives to build good pharmacokinetic properties and 16 
safety profile were required. Recently, QSAR study have been applied to identify the 17 
structural requirement of DNA gyrase inhibitors including fluoroquinolone [29-31], 18 
isothiazoloquinolone [31] and quinoline-aminopiperidine [32] derivatives.  However, 19 
information of the key structural features of inhibitors responsible to both enzyme and 20 
bacterial cell inhibition were not reported. In the present study, QSAR approaches and 21 
MD simulations were performed to gain insight into the key structural features of thiazole 22 
urea core derivatives responsible to GyrB and mycobacterial inhibitions. The obtained 23 
results revealed the key structural structure that serve as template in designing for high 24 
potency of DNA gyrase inhibitors. The finding concept in the present study were applied 25 
to design novel thiazole urea derivatives. In addition, pharmacokinetic properties of novel 26 
designed thiazole urea derivatives were considered. Compounds with high predictions of 27 
GyrB enzyme inhibition and mycobacterial inhibition that showed good pharmacokinetic 28 
properties were proposed.       29 
 
 
Material and Methods 1 
Compound dataset 2 
55 thiazole urea core derivatives including thiazolopyridinone urea, 3 
thiazolopyridine urea and benzothiazole urea derivatives (Table 1) with GyrB ATPase 4 
inhibition activity (inhibition concentration of compound required for ATPase inhibition 5 
activity at 50% (IC50) in nanomolar concentration unit) and anti-mycobacterial activity 6 
(minimum inhibitory concentration (MIC) in micromolar concentration unit) were 7 
collected from the literature [27, 28]. The general scaffolds, thiazolopyridinone urea 8 
(scaffold A), thiazolopyridine urea (scaffold B) and benzothiazole urea (scaffold C) of 9 
the molecules are depicted in Figure 1. These derivatives shared the thiazole urea core 10 
structure and the inhibitory activities against GyrB and mycobacterial cell of these 11 
inhibitors were measured by M. smegmatis GyrB ATPase assay and M. tuberculosis 12 
H37Rv cell on MABA assay in the same laboratory. The IC50 and MIC values of the 13 
collected thiazole urea derivatives are in the range from 0.5 to 217 nM and 0.06 to 21 14 
µM. Three-dimensional coordinate of inhibitors was downloaded from CHEMBL 15 
database and used as initial coordinate for structure optimizations. M062X/6-31G* basis 16 
set implemented in Gaussian 09 program was applied for structural optimizations. The 17 
biological activities of thiazole urea core derivatives were converted into log(1/IC50) and 18 
log(1/MIC) for GyrB inhibitory activity and anti-mycobacterial activity to reduce the 19 
range of biological activities, which serves as dependent variable for QSAR study. 20 
Thiazole urea core derivatives were classified as two datasets, training set for QSAR 21 
model construction and test set for validations of QSAR model. 9 compounds of test set 22 
were selected by consideration of the structural diversity and the biological activity range 23 
of thiazole urea derivatives.   24 
 25 
[Figure 1.] 26 
[Table 1.] 27 
HQSAR studies 28 
HQSAR approach [32] was performed using SYBYL X-2.0 [33] to investigate 29 
the structural requirement for improving the biological activities. 55 GyrB inhibitors were 30 
 
 
classified into two main classes, training set (46 compounds, 84 %) and test set (9 1 
compounds, 16 %). For HQSAR analysis, four molecular fragments, atom (A), bond (B), 2 
component (C) and donor and acceptor (DA) were selected as the independent molecular 3 
descriptors and biological activities were used as dependent variable for HQSAR model 4 
contractions. To develop robust HQSAR models, numerous models with various 5 
combinations of the fragment-distinction properties were constructed. Partial least square 6 
(PLS) was used to contrast the models of relationship of HQSAR descriptors and 7 
biological activity (log(1/IC50) or log(1/MIC)). The best HQSAR model was selected 8 
depending based on leave-one-out cross-validation (q2) higher than 0.6, lower standard 9 
error (SE) value and the best cross-validated r2.   10 
3D-QSAR studies 11 
CoMFA [34,35] and CoMSIA [36] approaches were performed using SYBYL X-12 
2.0. The data set to set up CoMFA and CoMSIA model is the same set used in HQSAR 13 
approach. The pharmacophore alignment module with the Genetic Algorithm with Linear 14 
Assignment for Hypermolecular Alignment of Datasets (GALAHAD) was used as 15 
molecular alignment tool for thiazole urea derivatives. GALAHAD is a developed 16 
program that uses genetic algorithm (GA) to generate pharmacophore hypotheses by 17 
ranging of energy profile, specificity value, and Pareto ranking [37-40] based on shared 18 
pharmacophoric and pharmacosteric features. The best docking conformation of the most 19 
active compound, compound 51 was used as template coordinate for molecular alignment 20 
for 3D-QSAR CoMFA and CoMSIA studies. GALAHAD was run for 20 maximum 21 
iterations with a population size of 40 with 20 pharmacophore models creations. The 22 
conformation that aligned to best pharmacophore model was selected. CoMFA 23 
descriptors, steric (S) and electrostatic (E) were calculated in standard settings with the 24 
energy cut-off values of 30 kcal/mol. The CoMSIA similar indices descriptors including 25 
steric (S) and electrostatic (E), hydrophobic (H), hydrogen-bond donor (D) and hydrogen-26 
bond acceptor (A) fields with attenuation factor α value of 0.3 and a grid spacing of 2 Å 27 
were calculated. After descriptor generation, PLS methodology was performed to find the 28 
correlation between dependent variables (log(1/IC50) or log(1/MIC)) and independent 29 
variable (CoMFA and CoMSIA descriptors). The q2 of model higher than 0.6 with highest 30 
r2 were used to evaluate the predictive ability of 3D-QSAR models and used as the criteria 31 
to accept the best and reliable 3D-QSAR model.  32 
 
 
Molecular docking calculations 1 
GyrB ATPase domain of Mycobacterium smegmatis (M. smegmatis) complexed 2 
with RWX (2-[(3S,4R)-4-[(3-bromanyl-4-chloranyl-5-methyl-1H-pyrrol-2-yl)carbonyl 3 
amino] -3-methoxy-piperidin-1-yl]-4-(2-methyl-1,2,4-triazol-3-yl)-1,3-thiazole-5-4 
carboxylic acid) (PDB code 4BAE)  was downloaded from protein databank and was used 5 
as receptor coordinate for molecular docking [22]. Molecular docking was employed 6 
using Autodock 2.4 program. The docking parameter was validated by docking of RWX 7 
into the binding site. RWX ligand was used as centre of grid box (size 42×42×42 point) 8 
with 0.375 Å spacing. The defeat docking parameter with 300 run of Lamarckian Genetic 9 
Algorithm (LGA) were applied [41]. The RMSD between docked and x-ray conformation 10 
lower than 1 Å (0.72±0.06, n=3) was used as criteria for acceptable docking parameters. 11 
All selected thiazole urea core compounds for MD simulations were docked into the GyrB 12 
ATPase binding size using the same docking parameter of RWX compound. The lowest 13 
docking energy conformation was selected as the binding mode of thiazole urea cores in 14 
the active site of GyrB ATPase. 15 
MD simulations 16 
The binding mode and binding interactions of selected derivatives were discussed 17 
in the original paper of thiazole urea derivatives. However, these results were obtained 18 
from flexible-rigid docking calculations [28]. To obtain reliability and accuracy of the 19 
binding mode and binding interactions of thiazole derivative in GyrB ATPase binding 20 
site in the solvation system and full flexibility of GyrB ATPase, six thiazole urea core 21 
derivatives covering the range of the most active to low active compounds were selected 22 
for MD simulations. Compound 51 is represented as the most active compound with IC50 23 
of 0.5 nM, whereas compounds 55 with IC50 value of 160 nM is representative compound 24 
possessing weak inhibitory activities against GyrB. Moreover, compounds 25, 26, 30 and 25 
35 are represented as moderate compounds. The IC50 values of moderate compounds are 26 
in range of 3.7 to 88 nM. MD simulations using AMBER16 package [42] was employed 27 
to elucidate the binding model and their crucial binding interactions in GyrB ATPase 28 
domain. The initial structure of GyrB ATPase-thiazole urea core complexes were 29 
obtained from flexible-rigid docking calculations using Autodock 4.2 as described in 30 
molecular docking calculations section above. FF14SB [43] and general amber force field 31 
(GAFF) [44] were applied as parameter for GyrB ATPase and thiazole urea core ligands, 32 
 
 
respectively. All missing hydrogen atoms of GyrB ATPase were added using the LEaP 1 
module. The restrained electrostatic potential (RESP) partial charges calculated at HF/6-2 
31G* [45] were assigned as atomic charges of thiazole urea core ligands by the 3 
antechamber module implemented in the AMBER16 package. Each complex structure 4 
was solvated by cubic box of TIP3P [46] water molecules extending up to 10 Å from each 5 
solute species. Sodium cations (Na+) were added to neutralize the charge of each system. 6 
To relax the bad steric interaction of water molecules and ions, the systems were first 7 
minimized with atomic positions of all solute species restraint (using a force constant of 8 
500 kcal mol−1 Å-2) with 2,500 steps of steepest descents followed by 20,000 steps of 9 
conjugated gradient. Non-bonded cut-off was set to 8 Å. Then, the system was gradually 10 
warmed up from 0 to 300 K in the first 20 ps followed by maintaining the temperature at 11 
300 K in the last 10 ps with 2 fs time simulation steps with a restraint weight of 2 kcal 12 
mol-1 Å -2. After minimization and heating step, the position-restrained dynamics 13 
simulations were applied to relax the positions of the solvent molecules for 70 ps at 300 14 
K under an isobaric condition. Finally, 100 ns of MD simulations were performed for 15 
each system without any restraints. The long-range electrostatic interactions were treated 16 
by the Particle Mesh Ewald method (PME) [47] and the cut-off distance for the long-17 
range van der Waals interaction was set to 8 Å. To constrain the bond lengths of hydrogen 18 
atoms attached to heteroatoms, the SHAKE method was applied [48].  19 
Binding free energy calculations 20 
Two binding free energy calculation approaches, MM-GBSA [49, 50] and 21 
waterswap calculations using Sire program [51, 52] were applied to estimate the binding 22 
affinity of GyrB ATPase-thiazole urea core inhibitor complexed. For MM-GBSA, 4,000 23 
snapshots during last 40 ns of MD simulations (after reached the equilibrium state) were 24 
collected for the binding free energy calculations. Whereas, the waterswap calculation 25 
approach used the final coordinate (100 ns of simulations) as initial structure for binding 26 
free energy calculations.  27 
Cluster analysis 28 
Cluster analysis was performed to determine the structure populations from MD 29 
simulations, structure from last 40 ns of MD simulations were collected for clustering 30 
analysis using cpptraj module [53] with average linkage. Distance cut-off for forming 31 
 
 
cluster was set at 1.5 Å. The average structure from the highest structure populations was 1 
selected for binding interaction analysis of thiazole urea cores in GyrB ATPase binding 2 
site. 3 
Hydrogen bond analysis 4 
The percentage and the number of hydrogen bond (H-bond) occupations between 5 
the selected thiazole urea core derivatives and the GyrB ATPase binding residues were 6 
identified according to the subsequent criteria: (i) the distance between hydrogen-bond 7 
donors (D) and hydrogen-bond acceptor (A) atoms ≤ 3.5 Å; and (ii) the D–H–A angle 8 
≥150 by cpptraj  module of AMBER16 to detect all hydrogen bonds during last 40 ns of 9 
MD simulations [53, 54].  10 
Results and Discussion 11 
QSAR models 12 
The highest predictive ability for each developed HQSAR, CoMFA and CoMSIA 13 
models was shown in Table 2 and 3, respectively. The best HQSAR-IC50 model was 14 
obtained with q2 and r2 values of 0.62 and 0.91, respectively. For the best HQSAR-MIC 15 
model, q2 and r2 values were 0.60 and 0.90, respectively. The best model for HQSAR-16 
IC50 and HQSAR-MIC contained three and four molecular fragment types which shared 17 
two combination fragment types, donor and acceptor features (DA) and connections (C).  18 
Only atoms (A) and bonds (B) were different combination to IC50 HQSAR and MIC 19 
HQSAR models, respectively. For 3D-QSAR model, only IC50 CoMSIA model including 20 
steric, electrostatic, hydrophobic and hydrogen donor fields was obtained with reliable q2 21 
value of 0.62 and r2 of 0.98. The contribution of steric, electrostatic, hydrophobic and 22 
hydrogen donor fields is 15%, 33%, 27% and 25%, respectively, indicating that the 23 
electrostatic field shows greatest influence on the activity of thiazole derivatives against 24 
GyrB inhibitory activity. Predicted biological activity of training set of IC50 CoMSIA, 25 
IC50 HQSAR and MIC HQSAR models were predicted and summarized in Table 4. To 26 
access the predictive abilities of each models, IC50 and MIC values of the test set were 27 
predicted as concluded in Table 4. The predicted activities of the training set are close to 28 
the experimental activities with highest deviation values of 0.25, 0.43 and 0.69 logarithm 29 
unit for IC50 CoMSIA, IC50 HQSAR and MIC HQSAR models, respectively. In addition, 30 
 
 
deviation values between experimental and predicted activity of test set for IC50 CoMSIA, 1 
IC50 HQSAR and MIC HQSAR models are 0.40, 0.40 and 0.44 (lower than one logarithm 2 
unit) indicated that the QSAR models obtained from this work can be utilized to predict 3 
the biological activity of newly design thiazole urea core derivatives.  The experimental 4 
and predicted activities of the IC50 CoMSIA, IC50 HQSAR and MIC HQSAR models 5 
reveal a linear relationship (Figure 2).  6 
[Table 2.] 7 
[Table 3.] 8 
[Table 4.] 9 
[Figure 2.] 10 
HQSAR atomic contribution and molecular fragment analysis 11 
Molecular fragments of thiazole urea core derivatives which contribute directly to 12 
biological activities of GyrB inhibition (IC50) and mycobacterial cell inhibition (MIC) 13 
can be visualized through HQSAR contribution maps. The HQSAR colour coding 14 
demonstrates the atomic contributions of the compounds with regards to biological 15 
activity. Green and yellow atomic contribution demonstrate a favourable contribution or 16 
positive contribution with regards to biological activity, whereas red, red-orange and 17 
orange indicate an unfavourable or negative contribution. White suggests an intermediate 18 
contribution of the atoms towards inhibitory activity. The atomic distributions of highest 19 
active compound 51, moderate active compound 37 and low active compound 4 with IC50 20 
HQSAR and MIC HQSAR were exposed in Figure 3. For the IC50 HQSAR model, the 21 
highest active compound 51 and moderate active compound 37 exhibited the important 22 
green and yellow fragments. In contrast, the lowest active compound (compound 4) only 23 
showed the bad fragments, orange and red fragments. The colour code labelling of MIC 24 
HQSAR model reveals that thiazole urea core is crucial for inhibitory activity responsible 25 
for GyrB enzyme and mycobacterial cell. R2 and R3 are positively favourable for anti-26 
mycobacterial activity as displayed in compound 51 (the highest active compound) and 27 
 
 
compound 37 (moderate active compound). The low active compound 4 were labelled by 1 
orange and red colour labelling. These results demonstrated that thiazole urea cores is key 2 
fragment for favorable to high potency on IC50 and MIC. In addition, R2 and R3 3 
substituents were favorable to improv the anti-mycobacterial activity.  4 
[Figure 3.] 5 
[Figure 4.] 6 
CoMSIA contour maps 7 
The structural requirement to improve GyrB inhibitory activity were derived from 8 
CoMSIA contour maps using the highest predictive ability IC50 CoMSIA model as 9 
displayed in Figure 5. The steric contour map was used to discriminate the steric structural 10 
requirement. Green and yellow contours were steric favourable and steric unfavourable, 11 
respectively. The electrostatic contour map was used to describe the effect of charge on 12 
the structural requirement of thizaole derivatives. Red and blue contour represent the 13 
negative charge and positive charge favourable, respectively. Magenta and white contour 14 
of CoMSIA hydrophobic contour map present the hydrophobic and hydrophilic 15 
properties favourable. The hydrogen bond donor and hydrogen bond favourable were 16 
suggested by cyan and purple contour maps, respectively. Cyan contour map located very 17 
closed to NH of urea fragment of thiazole urea core derivative indicate that hydrogen 18 
bond donor property of this fragment was required to enhance the biological activity. All 19 
data set compounds in this work contained this urea fragment. This is confirmed that urea 20 
part was crucial for biological activity of thiazole urea core derivatives. At R1 position, 21 
there is only one small yellow contour appeared. Therefore, small substituent or low steric 22 
hindrance substituent was required to improve the GyrB inhibitory activity. For example, 23 
compound 21 and compound 22 contained allyl and ethyl substituent of thiazole urea core 24 
scaffold A, respectively. The inhibitory activity (IC50) of compound 21 was 50 nM that 25 
showed the slightly higher inhibitory activity than compound 22 with IC50 value of 40 26 
nM. Compound 27 and 28 that represented as member of thiazole urea core scaffold B 27 
were presented with allyl and ethyl substituents on R1 position. Allyl substituent of 28 
compound 27 produced lower biological activity than ethyl substituent of compound 28 29 
with the IC50 of 46 nM and 25 nM for compound 27 and 28, respectively. At R2 position, 30 
the green, red and white contours were displayed demonstrate that steric with negative 31 
 
 
charge and hydrophilic properties were required for improving the biological activity of 1 
thiazole urea core derivatives. For the steric effect on R2 substituent, compounds 7, 9, 11, 2 
14 and 15 showed difference biological activity against GyrB because of substituent size 3 
of R2 position. The increasing size of 3-fluoro-pyrimidinyl (compound 7), 3-methoxy-4 
pyrimidinyl (compound 9), 3-cyano-pyrimidinyl (compound 11) and 1-alkyl-2(1H)-5 
pyridinonyl (compound 14 and 15)confirmed that the biological activity of thiazole urea 6 
core scaffold A (thiazolopyridinone) were increased for 10 nM, 6 nM, 4 nM, 5 nM and 7 
2.5 nM for compounds 7, 9, 11, 14 and 15, respectively. The biological activity of 8 
compounds 44, 45 and 46 (thiazole urea core scaffold B) demonstrate that increasing of 9 
substation on 3th position of pyridininyl substituent R2 enhanced the IC50 values of 12 10 
nM, 10 nM and 4 nM for compounds 44, 45 and 46, respectively. In addition, increasing 11 
size of aromatic ring of R2 substituent of thiazole urea core scaffold B were improved the 12 
biological activity as exemplified in compounds 46, 47 and 51. Compound 47 containing 13 
1-methylpyrazole substituent at R2 position showed the biological activity lower than 14 
compound 48 that contained 1-methyl-2(1H)-pyridinonyl substituent with IC50 values of 15 
10 nM and 1 nM for compounds 47 and 48, respectively. In addition, compound 51 16 
containing larger substituent size on 2(1H)-pyridinonyl than compound 47 showed the 17 
potency higher with the value of 0.5 nM and 1 nM, respectively. As considered with the 18 
effect of electrostatic property on R2 substituent, compounds 38, 39, 43, 44 and 48 were 19 
exemplified. Replacing H atom on pyridinyl ring of R2 substituent of compound 38 by 20 
high electronegativity fluorine atom (compound 39) or CN group (compounds 43 and 44) 21 
were considered. The biological activity of compounds 39 and 43 were increased as 22 
compared to compound 38 with the IC50 of 90 nM, 7 nM, 14 nM and 12 nM for 23 
compounds 38, 39, 43 and 44, respectively. Adding an oxygen carbonyl on R2 substituent, 24 
the biological activity of thiazole urea core derivative was increased as depicted by 25 
compounds 38 and 48. Pyridinyl substituent on compound 38 produced low biological 26 
activity than 1-methyl-2(1H)-pyridinonyl substituent on compound 48. The effect of 27 
hydrophobic property and hydrophilic properties of R2 position on the biological activity 28 
of thiazole urea core derivative was discriminated by compounds 6 and 18 in scaffold A. 29 
Compound 6 showed the inhibitory activity higher than 18 due to more hydrophilic 30 
favourable of pyrimidine of compound 6 as compared to pyridine ring of compound 18. 31 
Compounds 48-50 were used to exemplify the effect of hydrophilic property of R2 32 
position on thiazole urea core scaffold B derivatives. The increasing hydrophobic 33 
property of compounds 49 and 50 effected to lower inhibitory activity than compound 48. 34 
 
 
At R3 position of scaffold B, this position required the steric substituent to improve the 1 
biological activity. For example, compound 27 showed high potency than compound 26 2 
due to the steric substituent. In addition, compound 30 contained heterocyclic aliphatic 3 
substituent which they showed the potency higher than compound 34 (linear aliphatic 4 
chain). The hydrophobic substituent improved the biological activity of thiazole urea core 5 
scaffold B. For example, compounds 30, 31 and 32 which contained different R3 6 
substituent showed different inhibitory activities. Compound 30 with 3-7 
methyltetrahydrofuran displayed the potency higher than compounds 31 and 32 that 8 
contained tetrahydropyran and tetrahydrofuran substituents, respectively.  9 
 10 
[Figure 5.] 11 
MD simulations 12 
The root-mean square deviations (RMSD) over the simulations time of solute 13 
species, GyrB ATPase and selected ligands were calculated and plotted as shown in 14 
Figure 6.  MD simulations systems of GyrB ATPase and selected ligands reach the 15 
equilibrium state after 40 ns, 50 ns, 30 ns, 60 ns, 10 ns and 10 ns for compounds 25, 26, 16 
30, 35, 51 and 55, respectively. Therefore, the MD snapshots after 60 ns of the simulations 17 
time were selected for binding free energy calculations and structural analysis.    18 
 19 
[Figure 6.] 20 
 21 
The binding free energy of thiazole urea cores complexed with GyrB ATPase with 22 
two calculation methods were summarised in Table 4 and Figure 7. Both binding free 23 
calculation methods were corrected order of active compounds. The correlation (R2) 24 
between experimental binding free energy and calculated binding free energy from MM-25 
GBSA and waterswap are 0.52 and 0.85, respectively. In addition, waterswap calculations 26 
showed higher correlation than MM-GBSA approach. These results indicated that the 27 
binding mode of thiazole urea core derivatives are corrected based on the correlation 28 
between experimental and calculated binding free energy approved. The obtained results 29 
 
 
from these binding energy calculations demonstrated that the conformation obtained from 1 
MD simulations can produced the corrected order of binding free energy and GyrB 2 
inhibitory activity. Therefore, the finding binding mode from MD simulations is reliable 3 
for investigation of the binding mode and crucial interactions for binding of thiazole urea 4 
core derivatives in the GyrB ATPase domain.   5 
 6 
[Table 4.] 7 
[Figure 7.] 8 
The binding interactions of thiazole urea core derivatives in GyrB ATPase 9 
domain  10 
The binding mode of thiazole urea core derivatives was examined to investigate 11 
the key binding interactions in GyrB ATPase binding site.  The binding interactions of 12 
the highest active compound 51 was analysed and showed in Figure 8. Compound 51 13 
formed two hydrogen bond interactions with Asp79 and Arg141. A NH of urea fragment 14 
of thiazole urea core compound 51 interacted with oxygen atoms of Asp79 sidechain.  15 
Hydrogen atom of Asn52 point to thiazole aromatic ring of inhibitor and formed sigma-16 
pi interaction. Glu56 sidechain closed to thiazole ring and formed van der Waals 17 
interaction. Ethyl R1 substituent interacted with hydrophobic interaction with Val49, 18 
Ala53, Val65, Val77, Thr169 and Ile171 sidechain. An oxygen carbonyl of R2 substituent 19 
from hydrogen bond interaction with NH sidechain of Arg141. Cation-pi was obtained 20 
between guanidinium cation sidechain of Arg82 with aromatic ring of R2 substituent of 21 
compound 51. In addition, hydrophobic interactions of R2 substituent of this compound 22 
51 with Arg82, Gly83 and Pro85 were achieved. For R3 substituent of compound 51, this 23 
substituent contacted with Ile84, Pro85, Thr95, Val99, Leu120 and Val123 sidechains by 24 
hydrophobic interactions. These results were supported by the interaction energy using 25 
MM-GBSA calculation and hydrogen bond analysis as shown in Figure 9 and Figure 10.  26 
Figure 9e showed the binding interactions energy of compound 51. Large energy 27 
contribution was observed from the interaction of compound 51 with Asp79 with -12.0 28 
kcal/mol. In addition, the interaction energy of Arg141 with an oxygen of carbonyl group 29 
support the strong binding affinity of compound 51 with -8.1 kcal/mol. For all selected 30 
 
 
compounds, the binding interaction energy profiles were similar to the energy profile of 1 
compound 51 due to hydrogen bon interaction of nitrogen atom on pyridinyl substituent 2 
with Arg141, except compound 25. Compound 25 formed additional hydrogen bond 3 
interaction between an oxygen carbonyl of urea core with NH sidechain of Asn52.  Based 4 
on six selected compounds for MD simulation in this study, we found that three residues, 5 
Asn52, Asp79 and Arg141 of GyrB ATPase formed hydrogen interaction with thiazole 6 
urea core derivatives as shown in Figure 10. An oxygen atom of Asp79 sidechain act as 7 
hydrogen bond acceptor to bind with NH of urea of thiazole urea core derivatives along 8 
the hydrogen bond interaction with % hydrogen bond occupation higher than 50 %. This 9 
result suggested that hydrogen bond interactions were crucial interaction for binding with 10 
GyrB ATPase domain of thiazole urea core derivative via the hydrogen bond interactions 11 
with Asp79. In addition, hydrogen bond interaction with Arg141 of R2 substituents 12 
improved the biological activity of thiazole urea core derivatives against GyrB as shown 13 
in Figure 10. As compared to the docking results from original paper, the crucial 14 
interactions in ATPase binding site were similar. Asp79 interacted with NH of urea core 15 
via hydrogen bond interactions. Hydrogen bond interactions of an oxygen carbonyl and 16 
NH of Arg141 sidechain was also reported [28]. However, there are no hydrogen bond 17 
linker interactions water molecules by of nitrogen atom of thiazole ring with oxygen 18 
carbonyl of Asp79 sidechain and an oxygen carbonyl of urea core with NH of Asn52 19 
based on MD simulations and waterswap calculations in the present study. Therefore, 20 
water molecule doesn’t affect to the binding interactions of thiazole urea derivatives in 21 
ATPase binding site.  22 
 23 
[Figure 8.] 24 
[Figure 9.] 25 
[Figure 10.] 26 
The key structural feature of thiazole derivatives for highly potent biological 27 
activities  28 
In the present study, well-known QSAR approaches were carried out to 29 
understand the key structural requirements of thiazole urea derivatives responsible to both 30 
GyrB enzyme and mycobacterial cell. These finding provides the critical information to 31 
rational design of new highly potent thiazole urea inhibitors. Based on the MD 32 
simulations results, the quantitative information of binding mode and binding interactions 33 
 
 
was obtained from the solvation system by high accuracy of calculation method. The 1 
integrations of QSAR and MD simulations results provided the essential structural 2 
features for rational design of new and highly potent inhibitors with specific to GyrB 3 
ATPase binding site. The structural requirements and key interaction for binding of 4 
thiazole urea core derivatives for good potency against both IC50 and MIC derived from 5 
QSAR models and MD simulations approaches were summarized in Figure 11. Based on 6 
HQSAR, CoMSIA and MD simulations, the common structural features required for 7 
inhibition of GyrB enzyme and mycobacterial cell are revealed. The results of HQSAR 8 
based on two different biological activities, IC50 and MIC, suggest that the thiazole urea 9 
core was the key structure to obtain the inhibitory activities against both GyrB enzyme 10 
and mycobacterial cell. Urea fragment structure of thiazole urea core derivatives was 11 
crucial fragment for binding in GyrB ATPase binding pocket with hydrogen bond 12 
interactions with Asp79. These results demonstrated that thiazole urea core should be 13 
kept for good potency against both enzyme and bacterial cell. To improve the potencies, 14 
small substituent at R1 position was required to interact with hydrophobic side chain of 15 
GyrB. A R2 position, steric substituent like heterocyclic aromatic ring with hydrophilic 16 
property and suitable position of negative charge were required to bind with Arg82, 17 
Arg141 and hydrophobic residues via hydrogen bond interaction, cation-pi interaction 18 
and hydrophobic interactions, respectively. For R3 position, steric substituent with 19 
hydrophobic property was required to enhance the inhibitory activities of thiazole urea 20 
core derivatives. An extensive analysis of QSAR and MD simulations was very useful to 21 
design new drug candidates against GyrB ATPase targets. In addition, QSAR models can 22 
be an useful tool to guide further inhibitors design studies for the optimizations and 23 
development of new thiazole ureas having improved GyrB ATPase binding affinity. 24 
Considering the results obtained in the present study, the improvement of lead and 25 
candidate of the DNA gyrase inhibitors status in a series of thiazole urea derivatives. 26 
    27 
[Figure 11.] 28 
Rational design of novel thiazole urea derivatives 29 
Novel thiazole urea derivatives were designed based on our obtained results. The 30 
R2 and R3 substituents were modified, whereas thiazole urea core and the ethyl R1 31 
substituent were kept as the general structure. Heterocyclic aromatic rings were added to 32 
 
 
the R2 position with the aim for forming the cation-pi interaction with Arg82. Steric 1 
substituents with hydrophobic property were introduced to the R3 position. For designing 2 
new DNA gyrase inhibitors, the physicochemical properties and pan assay interference 3 
compounds (PAINS) violation were considered for the novel DNA gyrase inhibitors 4 
using SwissADME prediction [55]. The HQSAR-IC50 and HQSAR-MIC models were 5 
used to predict the biological activities of novel thiazole urea derivatives. 1,200 novel 6 
thiazole urea derivatives were designed based on the finding key structural features. In 7 
general, the log(1/IC50) and log(1/MIC) higher than 7.00 and 6.00 were required as potent 8 
GyrB inhibitor of thiazole urea derivative [28]. Based on HQSAR-IC50 and HQSAR-MIC 9 
predictions, 407 thiazole urea derivatives were collected based on log(1/IC50) and 10 
log(1/MIC) prediction higher than 7.00 and 6.00, respectively. preADME [56] was 11 
applied to predict the pharmacokinetic parameters of novel designed compounds as well 12 
as the most active compound 51 as shown in Table 5. The most active compound 51 13 
displayed low blood-brain barrier (BBB) penetration and plasma protein binding (PPB) 14 
with the values of 0.02 and 49.66%, respectively. Moderate value of MadinDarby Canine 15 
Kidney (MDCK) cell models for oral drug absorption was obtained with the value of 16 
4.64. High heterogeneous human epithelial colorectal adenocarcinoma cell lines (Caco2-17 
cell) and HIA were obtained with the values of 38.87 and 94.70, respectively. The BBB 18 
values of designed thiazole urea derivatives higher than the most active compound 51 19 
(>0.02) were considered. 200 compounds (Table S1) display the BBB values higher than 20 
the most active compound 51. D007 and D063 showed the highest predicted log(1/IC50) 21 
and log(1/MIC) with the values of 8.40 and 6.51, respectively. Their structures drug like 22 
properties and pharmacokinetic were summarized in Figure 12 and Table 5. The 23 
pharmacokinetic properties of designed compounds were acceptable, except MDCK cell 24 
level. Interestingly, PPB of novel designed compounds were higher than the most active 25 
compound 51. The binding modes of D007 and D063 were predicted using docking 26 
calculations. The binding energies of compounds D007 and D063 are -9.66 and -7.97 27 
kcal/mol, respectivelyindicating that these compounds are favourable for binding in 28 
ATPase domain of GyrB.  The predicted binding modes of compounds D007 and D063 29 
in ATPase binding pocket are shown in Figures 13a and 13b, respectively. NH of the urea 30 
core structure interacts with the oxygen carboxylate of Asp79 sidechain by hydrogen 31 
bond interactions. Cation-pi interaction with Arg82 was found between the aromatic R2 32 
substituent of both compounds (D007 and D063). In addition, the nitrogen atoms on 33 
pyrimidine ring of D007 and oxadiazole ring of D063 form the hydrogen bond 34 
 
 
interactions with Arg141. These results demonstrated that the novel designed compounds 1 
can be proposed as new DNA gyrase inhibitors with good pharmacokinetic properties and 2 
strongly bind with ATPase domain. 3 
 4 
[Figure 12] 5 
[Table 5] 6 
[Figure 13] 7 
Conclusion 8 
The key structural features of thiazole urea core derivative responsible for high 9 
potency against of GyrB and mycobacterial cell inhibition were successfully investigated 10 
by HQSAR, CoMSIA and MD simulations. IC50 HQSAR, MIC HQSAR and IC50 11 
CoMSIA models have high power to predict the activities of thiazole urea core 12 
derivatives. The reliable binding modes, binding free energy, and binding interactions of 13 
thiazole urea core derivatives in the GyrB ATPase binding pocket were obtained by MD 14 
simulations. Based on MD simulations, the crucial interactions of thiazole urea 15 
derivatives were corresponded well to previously report from the original paper. In 16 
contrast, water molecules were not stabilized the hydrogen interactions of thiazole urea 17 
derivatives with amino acid residues surrounding their binding site. The combination of 18 
graphical interpretation of QSAR results and MD simulations provides a key insight into 19 
the structural features needed to increase the IC50 and MIC values of thiazole urea core 20 
derivatives. Thiazole urea core and R2 substituent were required to attaining favorable 21 
IC50 and MIC values, whereas the R3 substituent is the key to enhance the potency against 22 
IC50. Therefore, the results obtained from this study should facilitate the further 23 
modification of thiazole urea core derivatives for generating novel DNA gyrase inhibitors 24 
with improved GyrB and mycobacterial cell inhibition potency. Therefore, novel thiazole 25 
urea derivatives with good predicted biological activities and pharmacokinetic properties 26 
were proposed as potent DNA gyrase inhibitors. 27 
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Table captions 1 














1 A Ethyl N N
N
 
Isopropyl 11 1.3 7.96 5.89 




Isopropyl 20 3 7.70 5.52 
3 A Ethyl N N
N
 
Isopropyl 16 0.8 7.80 6.10 




Isopropyl 217 12.5 6.66 4.90 





Isopropyl 2.5 0.2 8.60 6.70 
6 A Ethyl N
N
 
Isopropyl 23 2 7.64 5.70 




Isopropyl 10 11 8.00 4.96 
8 A Ethyl 
N OCH3
 
Isopropyl 23 10 7.64 5.00 




Isopropyl 6 4 8.22 5.40 
10 A Ethyl 
N CN
 
Isopropyl 15 21 7.82 4.68 




Isopropyl 4 4 8.40 5.40 







Isopropyl 20 1.6 7.70 5.80 





Isopropyl 5 0.5 8.30 6.30 





Isopropyl 5 0.3 8.30 6.52 






Isopropyl 2.5 0.3 8.60 6.52 
16 A Ethyl N
N
 
H 84 9 7.08 5.05 
17 A Ethyl N
 
Ethyl 30 2 7.52 5.70 
 
 
18 A Ethyl N
 
Isopropyl 40 2 7.40 5.70 





40 3 7.40 5.52 





25 8 7.60 5.10 





50 10 7.30 5.00 





40 7.3 7.40 5.14 




14 3 7.85 5.52 
24 B Ethyl N
N
 
Methoxy 22 2 7.66 5.70 









3.7 0.27 8.43 6.57 
26 B Allyl N
 
H 88 8 7.06 5.10 
27 B Allyl N
 
O
OCH3  46 10 7.34 5.00 
28 B Ethyl N
 
O
OCH3  25 2.8 7.60 5.55 






12 1.29 7.92 5.89 





5 1.3 8.30 5.89 





9 0.92 8.05 6.04 





13 1.54 7.89 5.81 





39 0.92 7.41 6.04 




OCH3  17 0.67 7.77 6.17 






10 0.2 8.00 6.70 






30 2 7.52 5.70 






30 1 7.52 6.00 






90 3.5 7.05 5.46 
 
 







7 0.9 8.15 6.05 






11 2 7.96 5.70 







8 1.7 8.10 5.77 






9 0.9 8.05 6.05 






14 0.4 7.85 6.40 







12 0.6 7.92 6.22 










10 4 8.00 5.40 









4 1 8.40 6.00 







10 1.8 8.00 5.74 








1 0.14 9.00 6.85 









4.6 0.14 8.34 6.85 










8 0.53 8.10 6.28 







0.5 0.06 9.30 7.22 







47 5 7.33 5.30 









3 3.1 8.52 5.51 








2.2 0.6 8.66 6.22 
55 C Allyl N
 
H 160 16 6.80 4.80 
* test set 1 
 2 
 3 
  4 
 
 
Table 2. The statistical results of HQSAR models. 1 
Activity Descriptor  q2 r2 s SEE N Hologram length 
log(1/IC50) DA/C/A  0.62 0.91 0.36 0.17 6 353 
log(1/MIC) DA/B/C/A  0.60 0.90 0.41 0.20 6 71 
A, atoms; B, bonds; C, connections; DA, donor and acceptor; q2, leave-one-out (LOO) 2 
cross-validated correlation coefficient; r2, non-cross-validated correlation coefficient; N, 3 
optimum number of components; s, standard error of prediction; SEE, standard error of 4 
estimate 5 
 6 
  7 
 
 
Table 3. The statistical results of CoMFA and CoMSIA models. 1 
Activity Descriptor q2 r2 S SEE F N Fraction 
log(1/IC50) 
CoMFA        
S/E 0.47 0.90 0.42 0.18 96.69 4 40/60 
CoMSIA        
S/E/H/D 0.62 0.98 0.36 0.08 388.93 6 15/33/27/25 
log(1/MIC) 
CoMFA        
S/E 0.33 0.77 0.50 0.30 46.12 3 40/60 
CoMSIA        
S/E/H 0.39 0.73 0.48 0.32 58.40 2 17/38/45 
S steric field; E electrostatic field; H hydrophobic field; D hydrogen donor field; A 2 
hydrogen acceptor field; q2, leave-one-out (LOO) cross-validated correlation 3 
coefficient; r2, non-cross-validated correlation coefficient; N optimum number of 4 
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Table 4. Experimental and predicted activities for training and test set in CoMSIA and 1 
HQSAR models. 2 
Cpd. Scaffold 
log(1/IC50) log(1/MIC) 
Exp. CoMSIA Res. HQSAR Res. Exp. HQSAR Res. 
1 A 7.96 8.01 -0.05 7.95 0.00 5.89 5.81 0.08 
2* A 7.70 7.92 -0.22 7.61 0.09 5.52 5.60 -0.08 
3 A 7.80 7.86 -0.06 7.98 -0.18 6.10 6.19 -0.09 
4 A 6.66 6.57 0.09 6.61 0.06 4.90 4.99 -0.08 
5* A 8.60 8.20 0.40 8.51 0.10 6.70 6.25 0.44 
6 A 7.64 7.61 0.03 7.75 -0.11 5.70 5.52 0.18 
7 A 8.00 8.05 -0.05 8.03 -0.03 4.96 4.77 0.19 
8 A 7.64 7.64 0.00 7.75 -0.11 5.00 5.07 -0.07 
9 A 8.22 8.28 -0.06 7.99 0.23 5.40 5.15 0.25 
10 A 7.82 7.71 0.12 7.75 0.08 4.68 5.17 -0.49 
11 A 8.40 8.43 -0.03 7.97 0.43 5.40 5.68 -0.29 
12 A 7.70 7.66 0.03 7.54 0.16 5.80 5.84 -0.04 
13 A 8.30 8.29 0.02 8.39 -0.09 6.30 6.25 0.05 
14* A 8.30 8.12 0.19 8.70 -0.40 6.52 6.41 0.12 
15 A 8.60 8.60 0.00 8.63 -0.03 6.52 6.59 -0.07 
16 A 7.08 7.08 -0.01 7.09 -0.02 5.05 5.10 -0.05 
17 A 7.52 7.57 -0.04 7.52 0.00 5.70 5.36 0.34 
18 A 7.40 7.40 -0.01 7.76 -0.36 5.70 5.31 0.39 
19 A 7.40 7.45 -0.05 7.43 -0.03 5.52 5.46 0.06 
20* A 7.60 7.94 -0.34 7.55 0.05 5.10 5.24 -0.14 
21 A 7.30 7.39 -0.08 7.32 -0.02 5.00 5.09 -0.09 
22 A 7.40 7.39 0.01 7.49 -0.09 5.14 5.37 -0.24 
23 A 7.85 7.85 0.01 7.70 0.16 5.52 5.50 0.02 
24 B 7.66 7.65 0.01 7.75 -0.09 5.70 5.91 -0.21 
25 B 8.43 8.41 0.03 8.67 -0.24 6.57 6.69 -0.12 
26 B 7.06 7.09 -0.03 7.03 0.02 5.10 5.02 0.08 
27 B 7.34 7.39 -0.05 7.41 -0.07 5.00 5.25 -0.25 
28 B 7.60 7.62 -0.02 7.58 0.03 5.55 5.54 0.02 
29 B 7.92 7.90 0.02 7.64 0.28 5.89 5.68 0.21 
30 B 8.30 8.33 -0.03 7.98 0.32 5.89 6.07 -0.18 
31 B 8.05 7.98 0.07 7.97 0.07 6.04 6.13 -0.09 
32* B 7.89 7.89 0.00 7.78 0.11 5.81 5.93 -0.12 
33 B 7.41 7.23 0.17 7.72 -0.31 6.04 5.88 0.16 
34 B 7.77 7.77 0.00 7.67 0.10 6.17 6.04 0.13 
35 B 8.00 7.94 0.06 8.07 -0.07 6.70 6.57 0.12 
36* B 7.52 7.83 -0.31 7.29 0.23 5.70 5.68 0.02 
37 B 7.52 7.57 -0.04 7.39 0.14 6.00 5.97 0.03 
38 B 7.05 7.03 0.01 7.05 0.00 5.46 5.54 -0.09 
39 B 8.15 8.22 -0.07 8.10 0.06 6.05 6.19 -0.14 
40* B 7.96 8.15 -0.19 7.97 -0.01 5.70 5.95 -0.25 
 
 
41 B 8.10 8.19 -0.10 8.19 -0.09 5.77 5.72 0.05 
42* B 8.05 8.24 -0.19 7.99 0.05 6.05 6.02 0.03 
43 B 7.85 7.93 -0.08 7.97 -0.11 6.40 5.98 0.41 
44 B 7.92 7.91 0.01 8.18 -0.26 6.22 6.39 -0.17 
45 B 8.00 7.91 0.09 8.14 -0.14 5.40 5.51 -0.12 
46 B 8.40 8.41 -0.01 8.30 0.10 6.00 5.82 0.18 
47 B 8.00 8.06 -0.06 8.11 -0.11 5.74 5.75 0.00 
48 B 9.00 8.75 0.25 8.72 0.28 6.85 6.77 0.08 
49 B 8.34 8.36 -0.02 8.41 -0.07 6.85 6.97 -0.12 
50 B 8.10 8.24 -0.14 8.16 -0.06 6.28 6.39 -0.11 
51 B 9.30 9.22 0.09 9.15 0.16 7.22 7.07 0.15 
52* B 7.33 7.67 -0.35 7.34 -0.01 5.30 5.72 -0.42 
53 B 8.52 8.58 -0.05 8.58 -0.05 5.51 5.75 -0.24 
54 B 8.66 8.65 0.01 8.58 0.08 6.22 5.97 0.25 
55 C 6.80 6.80 -0.01 6.83 -0.04 4.80 4.90 -0.10 
*test set 1 
 2 
  3 
 
 
Table 4. Binding free energy of thiazole urea core derivatives from MM-GBSA and 1 
waterswap calculations. 2 
Cpd. IC50(nM) 
Energy (kcal/mol) 
GExp.* H TS GMM-GBSA Gwaterswap 
25 3.7 -11.58 -49.25  -21.24  -28.01  -36.57  
26 88 -9.69 -46.56  -25.58  -20.98  -32.12  
30 5 -11.40 -49.50  -17.58 -31.92  -33.74  
35 10 -10.99 -48.89  -20.73  -28.16  -34.62  
51 0.5 -12.77 -59.24  -21.86  -37.38  -45.38  
55 160 -9.33 -48.48  -18.69  -29.79  -23.81  
*Experimental binding free energy (GExp.) was calculated from GExp. = -RTln[IC50]. Whereas, 3 
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Table 5. Predicted biological activities, docking score and pharmacokinetic prediction 1 
of novel thiazole urea derivatives 2 
 Compound 51 D007 D063 
HQSAR-IC50 8.93 8.40 8.01 
HQSAR-MIC 6.63 6.21 6.51 
Autodock 4.2 docking score (kcal/mol) -8.62 -9.66 -7.97 
BBB 0.02 0.05 0.04 
Caco2 38.87 15.72 12.58 
CYP2C19 inhibition Non Non Non 
CYP2C9 inhibition Non Inhibitor Non 
CYP2D6 inhibition Non Non Non 
CYP2D6 substrate Non Non Non 
CYP3A4 inhibition Non Non Non 
CYP3A4 substrate Substrate Weakly Substrate 
HIA 94.70 90.50 87.84 
MDCK 4.64 0.89 17.99 
Pgp inhibition Non Non Non 
PPB 49.66 56.20 75.19 
Ames test mutagen mutagen mutagen 
Carcino Mouse negative negative negative 
Carcino Rat negative negative positive 
hERG inhibition low risk medium risk low risk 
BBB: Indicates BB (Cbrain/Cblood) ratio. Value > 0.1 suggested moderate absorption 3 
to CNS  4 
Caco2 permeability: Value of the Pcaco2 (nm/sec) < 4 indicates low permeability. 5 
HIA: Calculated HIA at pH 7.4:  Value between 70–100% indicates fair absorption 6 
PPB: Plasma protein binding: Value > 90% indicates strong protein binding 7 
MDCK cell level <25, the molecule is having low permeability 8 
 9 
  10 
 
 
Figure captions 1 
Figure 1. General structural scaffolds of thiazole urea core derivatives. 2 
 3 
  4 
 
 
Figure 2. Plot of experimental versus predicted biological values from each best IC50 1 
CoMSIA (a), IC50 HQSAR (b) and MIC HQSAR model (c). 2 
 3 
  4 
 
 
Figure 3. HQSAR contribution of thiazole urea core compounds derived from IC50 1 
HQSAR model. 2 
 3 
  4 
 
 
Figure 4. HQSAR contribution of thiazole urea core compounds derived from MIC 1 
HQSAR model. 2 
 3 
  4 
 
 
Figure 5. CoMSIA contour maps derived from the best IC50 CoMSIA model. 1 
 2 
  3 
 
 
Figure 6. RMSD plotted of GyrB ATPase complexed with thiazole urea core 1 
derivatives; compound 25 (a), compound 26 (b), compound 30 (c), compound 35 (d), 2 
compound 51 (e) and compound 55 (f). 3 
 4 
  5 
 
 
Figure 7. Correlation between experimental binding free energy and calculated binding 1 
free energy obtained from MM-GBSA (a) and waterswap calculation (b). 2 
 3 
  4 
 
 
Figure 8. The binding mode and binding interactions of the highest active compound 51 1 
obtained from MD simulations. Red and yellow dot line indicated hydrogen bond and 2 
cation-pi interactions, respectively. 3 
 4 
  5 
 
 
Figure 9. The binding interaction energy profile of thiazole urea core derivatives 1 
obtained from MM-GBSA calculations. 2 
 3 
  4 
 
 
Figure 10. The hydrogen bond contribution obtained from MD simulations of thiazole 1 
urea core derivatives in GyrB ATPase domain. 2 
 3 
  4 
 
 
Figure 11. The key structural feature of thiazole urea cores for good IC50 and MIC 1 
correlation summarized from HQSAR, CoMSIA and MD simulations results. Red and 2 
black letters indicate the results obtained from QSAR (HQSAR and CoMSIA) and MD 3 
simulations results, respectively. 4 
 5 
  6 
 
 
Figure 12. Structure and drug-like properties of novel thiazole urea derivatives. 1 
 2 
  3 
 
 
Figure 13. The binding mode and binding interactions of the D007 (a) and D063 (b) 1 
obtained from molecular docking calculations. Red and yellow dot line indicated 2 
hydrogen bond and cation-pi interactions, respectively. 3 
 4 
 5 
